Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication

Area of Science:

• Immunology
• Oncology
• Cancer Biology

Background:

• Disialoganglioside GD2 is overexpressed on neuroblastoma and other solid tumors.
• Anti-GD2 monoclonal antibodies improve outcomes in high-risk neuroblastoma but have limited efficacy in other GD2+ malignancies.
• Tumors evade immune detection by expressing CD47, a 'Don't eat me' signal that inhibits macrophage phagocytosis.

Purpose of the Study:

• To investigate the synergistic potential of combining anti-GD2 and anti-CD47 therapies.
• To elucidate the mechanisms driving the synergy between anti-GD2 and anti-CD47 in various cancer models.

Main Methods:

• Utilized syngeneic and xenograft mouse models of neuroblastoma, osteosarcoma, and small-cell lung cancer.
• Administered combination therapy of anti-GD2 and anti-CD47 antibodies.
• Analyzed macrophage activity and immune signaling pathways.

Main Results:

• The combination of anti-GD2 and anti-CD47 eradicated tumors in neuroblastoma models.
• Significant tumor burden reduction and extended survival were observed in osteosarcoma and small-cell lung cancer models.
• Synergy was attributed to GD2 ligation upregulating calreticulin ('Eat me' signal) and disrupting the GD2-Siglec-7 interaction.

Conclusions:

• The combination of anti-GD2 and anti-CD47 demonstrates potent anti-tumor activity across multiple cancer types.
• This combination strategy warrants clinical translation for treating GD2-expressing malignancies.
• CD47 blockade is most effective when combined with antibodies that modulate additional phagocytic signals.